Evidence map›Paper›PMID 30407503›Full record

ArticleThe international journal of neuropsychopharmacology2019

Inhibition of Phosphodiesterase 4 by FCPR03 Alleviates Chronic Unpredictable Mild Stress-Induced Depressive-Like Behaviors and Prevents Dendritic Spine Loss in Mice Hippocampi.

Hui Yu, Jiahong Zhong, Bo Niu, Qiuping Zhong, Jiao Xiao, Jinfeng Xie, Manna Lin, Zhongzhen Zhou, Jiangping Xu, Haitao Wang

Open access · goldAbstract read
In one paragraph

Article in The international journal of neuropsychopharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 28 citations in OpenAlex.

  1. Comparative Study on the Neuroprotective Effects of Perindopril and Benazepril in Experimentally-induced Chronic Mild Stress in Rats.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025
    Article
  2. Article
  3. Research progress on phosphodiesterase 4 inhibitors in central nervous system diseases.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2024
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Hui YuDepartment of Neuropharmacology and Drug DiscoverySouthern Medical University, Guangzhou, China.
Jiahong ZhongDepartment of Neuropharmacology and Drug DiscoverySouthern Medical University, Guangzhou, China.
Bo NiuDepartment of Neuropharmacology and Drug DiscoverySouthern Medical University, Guangzhou, China.
Qiuping ZhongDepartment of Neuropharmacology and Drug DiscoverySouthern Medical University, Guangzhou, China.
Jiao XiaoDepartment of Neuropharmacology and Drug DiscoverySouthern Medical University, Guangzhou, China.
Jinfeng XieDepartment of Neuropharmacology and Drug DiscoverySouthern Medical University, Guangzhou, China.
Manna LinDepartment of Neuropharmacology and Drug DiscoverySouthern Medical University, Guangzhou, China.
Zhongzhen ZhouDepartment of Neuropharmacology and Drug DiscoverySouthern Medical University, Guangzhou, China.
Jiangping XuDepartment of Neuropharmacology and Drug DiscoverySouthern Medical University, Guangzhou, China.
Haitao WangDepartment of Neuropharmacology and Drug DiscoverySouthern Medical University, Guangzhou, China.
Southern Medical University · CNGuangzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Phosphodiesterase 4 is a promising target for developing novel antidepressants. However, prototype phosphodiesterase 4 inhibitors show severe side effects, including nausea and vomiting. N-Isopropyl-3-(cyclopropylmethoxy)-4-difluoromethoxy benzamide (FCPR03) is a novel phosphodiesterase 4 inhibitor with little emetic potential. In the present study, we investigated the inhibitory effect of FCPR03 on chronic unpredictable mild stress-induced, depressive-like behaviors in mice and explored the underlying mechanisms. Methods: The depression model of mice was established by chronic unpredictable mild stress. Forced swim test, tail suspension test, and sucrose preference test were used to assess depressive-like behaviors. Golgi-staining was utilized to analyze dendritic morphology and spine density. The level of cAMP was measured by enzyme-linked immnosorbent assay assay. Western blot was used to evaluate protein levels of phosphorylated cAMP-response element binding protein, protein kinase B, glycogen synthase kinase-3β, and brain derived neurotrophic factor in both hippocampus and prefrontal cortex. Postsynaptic density protein 95 and synapsin 1 were also detected by western blot in the hippocampi. Results: Treatment with FCPR03 (0.5-1.0 mg/kg, i.p.) increased consumption of sucrose in the sucrose preference test in mice exposed to chronic unpredictable mild stress. FCPR03 shortened the immobility time in forced swim test and tail suspension test without affecting locomotor activity. Furthermore, chronic unpredictable mild stress decreased the dendritic spine density and dendritic length in the hippocampus. This change was accompanied by decreased expression of postsynaptic density protein 95 and synapsin 1. Interestingly, FCPR03 prevented dendritic spine loss and increased synaptic protein levels. Moreover, the levels of cAMP, phosphorylated cAMP-response element binding protein, and brain derived neurotrophic factor were elevated in chronic unpredictable mild stress-challenged mice after treatment with FCPR03. In addition, FCPR03 also enhanced the phosphorylation of both protein kinase B and glycogen synthase kinase-3β in mice exposed to chronic unpredictable mild stress. Conclusion: The present study suggests that FCPR03 could prevent both depressive-like behaviors and spine loss induced by chronic unpredictable mild stress in the mice hippocampi.

Indexed as

AnimalsBehavior, AnimalBenzamidesDendritic SpinesDepressionDisease Models, AnimalHippocampusMaleMiceMice, Inbred C57BLPhosphodiesterase 4 InhibitorsStress, PsychologicalBenzamidesN-isopropyl-3-(cyclopropylmethoxy)-4-difluoromethoxybenzamidePhosphodiesterase 4 Inhibitors

Identifiers

PMID30407503
PMCPMC6377503
OpenAlexW2900421465

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.